Skip to content
Hims & Hers Q1 2026 Earnings: Short-Term Pain, Long-Term Gain
Key takeaways
- Revenue rose only 4%, to $608 million, as Hims stopped promoting its own copies of weight-loss drugs and switched to branded Wegovy.
- Most of the $92 million net loss was charges management called one-time or non-cash; day-to-day operations still generated $89 million in cash.
- Branded Wegovy is ramping fast, with over 125,000 shipments in six weeks, though retention beyond the first month was not disclosed.
- Monthly shipping stacks up revenue, so management expects faster growth in the second half and raised full-year guidance to $2.8 to $3.0 billion.
- The video calls it short-term pain for long-term gain: the subscribers are the asset, and their data is the moat.